BURLINGAME, Calif. (AP) — BURLINGAME, Calif. (AP) — Corvus Pharmaceuticals Inc. (CRVS) on Tuesday reported a loss of $12.1 million in its fourth quarter. The Burlingame, California-based ...

Insiders who purchased Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) shares in the past 12 months are unlikely to be deeply impacted by the stock's 16% decline over the past week. After taking the ...

Corvus Pharmaceuticals highlighted significant progress for soquelitinib, including ongoing Phase 3 trials for T-cell lymphoma and advancements in atopic dermatitis studies. The company has ...

Miller, M.D., co-founder, president and chief executive officer of Corvus. "Our Phase 1 clinical trial in atopic dermatitis is nearing completion of enrollment in the third cohort at a dose level that ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Corvus’s four brightest stars form a distinctive shape resembling a lopsided square or trapezoid that makes it easy to locate. (Illustration by the author) Tucked away in the spring and summer evening ...

SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a ...